A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer

Nachimuthu Chinnasamy, Jennifer A. Wargo, Zhiya Yu, Mahadev Rao, Timothy L. Frankel, John P. Riley, Jenny J. Hong, Maria R. Parkhurst, Steven A. Feldman, David S. Schrump, Nicholas P. Restifo, Paul F. Robbins, Steven A. Rosenberg and Richard A. Morgan

J Immunol 2011; 186:685-696; Prepublished online 13 December 2010; doi: 10.4049/jimmunol.1001775
http://www.jimmunol.org/content/186/2/685
A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer

Nachimuthu Chinnasamy, Jennifer A. Wargo, Zhiya Yu, Mahadev Rao, Timothy L. Frankel, John P. Riley, Jenny J. Hong, Maria R. Parkhurst, Steven A. Feldman, David S. Schrump, Nicholas P. Restifo, Paul F. Robbins, Steven A. Rosenberg, and Richard A. Morgan

Adoptive immunotherapy using TCR-engineered PBLs against melanocyte differentiation Ags mediates objective tumor regression but is associated with on-target toxicity. To avoid toxicity to normal tissues, we targeted cancer testis Ag (CTA) MAGE-A3, which is widely expressed in a range of epithelial malignancies but is not expressed in most normal tissues. To generate high-avidity TCRs against MAGE-A3, we employed a transgenic mouse model that expresses the human HLA-A*0201 molecule. Mice were immunized with two HLA-A*0201–restricted peptides of MAGE-A3: 112–120 (KVAELVHFL) or MAGE-A3: 271–279 (FLWGPRALV), and T cell clones were generated. MAGE-A3–specific TCR α- and β-chains were isolated and cloned into a retroviral vector. Expression of both TCRs in human PBLs demonstrated Ag-specific reactivity against a range of melanoma and nonmelanoma tumor cells. The TCR against MAGE-A3: 112–120 was selected for further development based on superior reactivity against tumor target cells. Interestingly, peptide epitopes from MAGE-A3 and MAGE-A12 (and to a lesser extent, peptides from MAGE-A2 and MAGE-A6) were recognized by PBLs engineered to express this TCR. To further improve TCR function, single amino acid variants of the CDR3 α-chain were generated. Substitution of alanine to threonine at position 118 of the α-chain in the CDR3 region of the TCR improved its functional avidity in CD4 and CD8 cells. On the basis of these results, a clinical trial is planned in which patients bearing a variety of tumor histologies will receive autologous PBLs that have been transduced with this optimized anti–MAGE-A3 TCR. The Journal of Immunology, 2011, 186: 685–696.

In the past two decades, fundamental advances in immunology and tumor biology combined with the identification of a large number of tumor Ags have led to significant progress in the field of cell-based immunotherapy (1–4). Adoptive cellular immunotherapy involving transfer of tumor-reactive T cells has shown some notable antitumor responses in patients with metastatic melanoma. The administration of naturally occurring tumor infiltrating lymphocytes (TILs) expanded ex vivo mediated an objective response rate ranging from 50–70% in melanoma patients, including bulky invasive tumors at multiple sites involving liver, lung, soft tissue, and brain (3, 5). A major limitation to the widespread application of TIL therapy is the difficulty in generating human T cells with antitumor potential. It has been reported that approximately only half of melanomas reproducibly give rise to antitumor TILs (6). As an alternative approach, high-affinity TCRs can be introduced into normal T cells of the patients, and the adoptive transfer of these cells into lymphodepleted patients has been shown to mediate cancer regression (7, 8).

Adoptive transfer of TCR-transduced PBLs targeting melanoma differentiation Ags such as MART-1 and gp100 resulted in objective cancer regression in up to 30% of patients (7). However, patients also exhibited significant toxicity associated with destruction of normal melanocytes in the skin, eye, and ear (7). This trial revealed that T cells expressing highly reactive TCRs mediate cancer regression and also target cognate Ag-expressing cells throughout the body. Efforts to enhance adoptive immunotherapy response rates may hinge on targeting tumor Ags with little or no expression in normal tissue. In an effort to overcome the on-target toxicities associated with immunotherapies directed against Ags expressed on normal tissues, we and others have focused on generating TCRs targeting cancer testis Ags (CTAs). CTAs are immunogenic proteins, which are normally expressed in non-MHC-expressing germ cells of testis yet are aberrantly expressed in many tumors; thus, CTAs may represent ideal targets for tumor immunotherapy. More than 110 CTA genes or gene families have been identified that are expressed in multiple tumor types (9–11). These immunogenic proteins are being vigorously pursued as targets for therapeutic cancer vaccines and TCR-based adoptive immunotherapy (12–14). In theory, targeting T cells against tumor-associated CTAs might selectively eliminate tumor cells while avoiding toxicity to normal tissue.

Since the identification of the first human MAGE CTA gene in 1991, the number MAGE family genes have grown to >25 members (15, 16). MAGE-A is a multigene family consisting of 12 homologous genes MAGE-A1 to MAGE-A12 located at chromosome Xq28 (11). The precise function and biological role of MAGE proteins have not been completely elucidated. However, members of MAGE-A, MAGE-B, and MAGE-C proteins have...
TCR RECOGNIZING MULTIPLE MAGE GENES FOR CANCER GENE THERAPY

were obtained from the laboratory of Dr. David Schrump (Surgery H2122 (HLA-A*0201 line U251 (HLA-A*0201+/MAGE-A3+) was obtained from the Division of melanoma, (22), non-small cell lung carcinoma (NSCLC) (23), head and neck squamous cell carcinoma (24), hepatocellular carcinoma, (25) and multiple myeloma (26). The expression of MAGE-A3 has been shown to be higher in more advanced stages of the disease and is associated with poor disease prognosis (27–29). Several antigenic peptides that bind to HLA class I or class II molecules on tumor cells have been reported (30–36).

Because of its high expression in a wide array of tumor types, MAGE-A3 is an attractive target for cancer immunotherapy. In an effort to generate TCRs against MAGE-A3, we immunized transgenic mice expressing the HLA-A*0201 molecule with two MAGE-A3 peptides. In this report, we describe a TCR with a high avidity for similar peptides derived from MAGE-A3 and MAGE-A12 that also cross-reacts with related peptides from MAGE-A2 and MAGE-A6. Normal PBLs engineered with this TCR demonstrated potent cytolytic activity and secreted high levels of IFN-γ in response to HLA-A*0201+/MAGE+ tumor cells from multiple histologies. These findings suggest that the use of this TCR for adoptive immunotherapy may be valuable for the treatment of patients with cancers that express these gene products.

Materials and Methods

Cell lines and human PBLs

HLA-A*0201+/MAGE-A3+ melanoma cell lines 526, 624.38, 1300, and 2984 and non-HLA-A*0201 cell lines 397, 888, 938, 1359, and 1088 were established from surgically resected metastatic melanoma tumors and maintained at the Surgery Branch, National Cancer Institute, National Institutes of Health (Bethesda, MD). The HLA-A*0201+/MAGE-A3 2561R cell line was isolated from a surgically resected metastatic renal cell carcinoma. NSCLC line H1299 (HLA-A*0201+/MAGE-A3+); small cell lung carcinoma lines H2721 (HLA-A*0201+/MAGE-A3+), H2122 (HLA-A*0201+/MAGE-A3+), and H1250 (HLA-A*0201+/MAGE-A3+); and esophageal cancer cell line BE-3 (HLA-A*0201+/MAGE-A3+) were obtained from the laboratory of Dr. David Schrump (Surgery Branch, National Cancer Institute, National Institutes of Health). Breast cancer cell lines MDA-MB-435S (HLA-A*0201+/MAGE-A3+) were from American Type Culture Collection (Manassas, VA). Glioma cell line U251 (HLA-A*0201+/MAGE-A3+) was obtained from the Division of Cancer Treatment and Diagnosis Tumor Repository, National Cancer Institute, National Institutes of Health (Frederick, MD). The COST-A*0201, 293-A*0201, 397-A*0201, 1359-A*0201, MDA-MB-453S-A*0201, and H1299-A*0201 cells were retrovirally engineered to express HLA-A*0201 as described previously (14, 37). COST-A*0201+/MAGE-A3, COST-A*0201+/MAGE-A12, 293-A*0201+/MAGE-A3, and 293-A*0201+/MAGE-A12 cells were transduced with a retroviral vector expressing the respective MAGE genes. T2 is a lymphoblastoid cell line lacking TAP function, whose HLA class I proteins can be easily loaded with exogenous peptides.

All of the PBLs used in this study were obtained from melanoma patients treated in the Surgery Branch, National Cancer Institute, National Institutes of Health, on Institutional Review Board-approved protocols. Human lymphocytes were cultured in AIM-V medium (Invitrogen, Carlsbad, CA) supplemented with 5% human serum from donors of blood group AB (Valley Biomedical, Winchester, VA), 50 U/ml penicillin, 50 μg/ml streptomycin (Invitrogen), and 300 IU/ml β-2–2 and maintained at 37°C with 5% CO2. Marine lymphocytes were cultured in RPMI 1640 supplemented with 10% FBS, 2 mmol/l-L-glutamine, 1 mmol/l sodium pyruvate, MEM nonessential amino acids, 55 μmol/l 2-ME, 50 U/ml penicillin, 50 μg/ml streptomycin, and 30 IU/ml recombinant human IL-2 (rhIL-2) (R10) (Invitrogen).

Quantitative real-time PCR for MAGE-A3/6 and MAGE-A12 expression

Total RNA from tumor cell lines was isolated using an RNasey kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. A total of 1 μg of RNA was then used for cDNA synthesis using oligo(dT) with the SuperScript First-Strand Synthesis Kit (Invitrogen). The cDNA was used as the templates for subsequent real-time PCR with primers designed specifically for MAGE-A3/6 (38), MAGE-A12, and β-actin (TaqMan Gene Expression Assays; Applied Biosystems, Foster City, CA). Each experiment was performed in duplicate using a TaqMan 7900 (Applied Biosystems) real-time PCR machine according to the manufacturer’s instructions. Absolute numbers of copies were estimated using standard curves with plasmid DNA expressing respective genes.

Synthetic peptides

The following peptides were used in this study: MAGE-A1: 105–113 (KVADLVYGL), MAGE-A2: 112–120 (KMVELVHLF), MAGE-A3: 112–120 (KVAELVHLF), MAGE-A3: 271–279 (FLWGPRALV), MAGE-A4: 113–121 (KVDLAEHLK), MAGE-A6: 112–120 (KVKALVHLFK), MAGE-A8: 115–123 (KVAELVRFL), MAGE-A12: 112–120 (KMAELVHLF), and MAGE-C2: 144–152 (KVAELVFL). The peptides were synthesized using a solid-phase method based on Fmoc chemistry with one of two multiple peptide synthesizers (model AMS 422; Gilson, or Pioneer: Applied Biosystems). Purity of the peptides was verified by mass spectrometry. Peptides were dissolved in DMSO and diluted in RPMI 1640 medium.

Immunization of HLA-A*0201 transgenic mice and isolation of TCRs

Transgenic mice expressing the full-length human HLA-A*0201 gene were obtained from The Jackson Laboratory. Mouse studies were conducted according to the protocols approved by the National Cancer Institute Animal Care and Use Committee as described previously (37). Briefly, 8- to 12-wk-old mice were immunized s.c. at the base of the tail with 100 μg of MAGE-A3: 112–120 (KVAELVHLF) or MAGE-A3: 271–279 (FLWGPRALV) plus 120 μg of hepatitis B virus core: 128–140 helper peptide (TPAPYRPNNAPIL) emulsified in 100 μl of IFA (Montanide ISA-51). A booster immunization was given 1 wk later. One week after the booster immunization, mice were euthanized and splenocytes were harvested and stimulated in vitro with irradiated T2 cells (18,000 rad) loaded with 0.01, 0.1, or 1 μg/ml of the immunizing peptide in R10 medium containing 30 IU/ml rhIL-2. Cultures were set up in 24-well plates with 1–3 million splenocytes and 0.2–0.4 million peptide-loaded T2 cells. One week after stimulation, bulk murine T cell cultures were tested in coculture assays for peptide-specific reactivity using T2 cell and tumor cell recognition using 1300 melanoma and H1299-A*0201 cells. AntispecIFN-γ secretion was measured by ELISA (Thermo Scientific, Rockford, IL). Peptide-reactive bulk cultures were cloned at 10 cells per well in a bottom 96-well plates with 5 × 105 peptide-pulsed irradiated T2 cells and 5 × 105 irradiated (3000 rad) CS7BL/6 feeder splenocytes in medium containing 30 IU/ml recombinant human IL-2. Two to three weeks later, growth-positive wells were identified, and the T lymphocytes from those wells were transferred into 48-well plates and stimulated with 2 × 105 peptide-pulsed irradiated T2 cells and 1 × 105 irradiated CS7BL/6 splenocytes in medium containing 30 IU/ml rhIL-2. One to 2 wk later, these T cell cultures were evaluated for specific recognition of peptide and tumor cells by means of specific IFN-γ secretion. T cells from each of the tumor-reactive clones were expanded by restimulation as described previously, and the total RNA was extracted for TCR isolation.

Cloning of MAGE-A3–specific, HLA-A*0201–restricted TCRs

Total RNA was extracted from tumor-reactive T cell clones using an RNasey mini kit (Qiagen). TCR α- and β-chains from each tumor-reactive T cell clone were cloned using the SMART RACE cDNA amplification kit (Clontech, Mountain View, CA). For the amplification of TCRs, gene-specific primers were made from the C region of mouse TCR α- and β-chains, TCR α C region-5′-ACTGTTACACAGCAGTCTG-3′ and TCR β C region-5′-AAGGAGACCTTGGGTTGAGTC-3′. The PCR products of the 5′-RACE were cloned into the PC2.1 TOPO vector (Invitrogen Life Technologies), and the insert DNA fragments were sequenced. The DNA sequence data were analyzed using The International Immunogenetics Information System (http://imgt.cines.fr/IMGT_vquest/vquest?livret=0&Option=mouseTcR) for the identification of mouse TCR α- and β-chains. After the identification of the variable regions of α- and β-chains and the identification of the C region
of the β-chain (CB1 or CB2), specific primers were used to amplify the full-length TCR α- and β-chains from the cDNA.

**Electroporation of TCRs into PBLs**

The full-length α- and β-chains were individually cloned into the RNA expression vector pGEM-4Z/64A. In vitro-transcribed mRNA encoding α- and β-chains were generated using mMESSAGE mMACHINE (Ambion, Austin, TX) and electroporated into OKT3-stimulated human lymphocytes with an ElectroSquarePorator ECM-830 (BTX, San Diego, CA) as described previously (39). Electroporated PBLs were tested for Ag-specific reactivity using peptide-loaded T2 cells and tumor cell lines 2361-RCC, 938 melanoma, H1299-A*0201, and 1300 melanoma. The Ag-specific response of TCR-electroporated T cells was evaluated by coculture with respective MAGE-A3 peptide-loaded T2 cells and tumor cell lines, and the culture supernatants were tested for IFN-γ levels by ELISA.

**Construction of retroviral vectors expressing MAGE-A3–specific HLA-A*0201–restricted TCRs**

Two MSGV1-based retroviral vectors were constructed using the overlapping PCR method with the transgene construct arranged in the following order of configuration: TCR α-chain, linker peptide furin-SGSG-P2A (13), and TCR β-chain. The cloned TCR inserts were verified by restriction enzyme digestion and DNA sequencing.

---

**FIGURE 1.**


**FIGURE 2.**

A and B, Recognition of peptide-pulsed T2 cells by the MAGE-A3 TCR-transduced PBLs. Human PBLs expressing TCR against MAGE-A3: 112–120 or MAGE-A3: 271–279 were cocultured for 16 h with T2 cells that were previously pulsed with different concentrations of the respective peptides. Coculture of PBLs expressing TCR against MAGE-A3: 112–120 or MAGE-A3: 271–279 with control T2 cells that were not pulsed with peptides produced background levels of IFN-γ. The concentration of IFN-γ secreted into the culture medium was measured by ELISA.
**Transduction of PBLs**

Retroviral supernatants were generated by transfecting respective MSGV1-MAGE-TCR vector DNA from each of the constructs with a plasmid encoding RD114 envelope into 293-GP cells using the Lipofectamine 2000 reagent (Invitrogen) in Opti-MEM medium (Invitrogen) (13). Retroviral vector expressing TCR against NY ESO-1 was used as a positive control in all of the experiments (12). MSGV1 vector expressing GFP was also generated. Viral supernatants were then loaded onto RetroNectin-coated (Takara Bio, Japan) non-tissue culture-treated six-well plates. PBLs were stimulated with OKT3 (50 ng/ml) and rhIL-2 (300 IU/ml) 48 h prior to transduction, and the transduction was carried out as described previously (13, 40).

**Tetramer staining**

HLA-A*0201–restricted MAGE-A3–derived peptides MAGE-A3: 122–120 (KVAELVHFIL) and MAGE-A3: 271–279 (FLWGRPALV) were used by the National Institute of Health T Cell Gateway Core Facility at Emory University to produce tetramers linking PE as the fluorophore. MAGE-A3 TCR-transduced T cells were stained with a FITC-labeled anti-CD8 (BD Pharmingen, San Jose, CA) and with PE-labeled HLA-A*0201 tetramers. FITC-conjugated mAb against the C region of the murine β-chain (eBioscience, San Diego, CA) and PE-conjugated anti-CD8 Abs were also used to detect the expression of MAGE-A3 TCRs in the human PBLs. Cells were analyzed using a FACScan flow cytometer with CellQuest software (BD Biosciences) or FlowJo software (Tree Star, Ashland, OR).

**Intracellular cytokine staining**

Intracellular cytokine staining was performed using a BD Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s instructions. Briefly, cells were first stained with cell surface markers CD3 and CD8 and then stained with FITC-conjugated anti–IFN-γ and allophycocyanin-conjugated anti–IL-2 Abs for intracellular detection of the cytokines. All of the Abs as well as isotype controls were purchased from BD Biosciences. Cells were analyzed using a FACSCanto II flow cytometer with CellQuest software (BD Biosciences) or FlowJo software (Tree Star).

**CD107α mobilization assay**

The cell surface mobilization of the CD107α molecule was determined as a measure of degranulation and functional reactivity after Ag recognition by the TCR. In these assays, 1 × 10⁶ H1299-A2 or H1299 cells were cocultured with an equal number of PBLs at 37˚C for 2 h. The cells were then stained with mouse anti-human Abs against CD107α and CD8 (BD Biosciences) and analyzed by FACS.

**Cytokine release assay**

TCR-engineered PBLs were tested for Ag-specific reactivity in cytokine release assays using peptide-loaded T2 cells and tumor cells. In these assays, effector cells (1 × 10⁵) were cocultured with an equal number of target cells in AIM-V medium in a final volume of 0.2 ml in duplicate wells of a 96-well U-bottom microplate. Culture supernatants were harvested 18–24 h after the initiation of coculture and assayed for IFN-γ and GM-CSF by ELISA (Thermo Scientific).

**[51Cr] release assay**

The ability of the transduced PBLs to lyse HLA-A*0201/MAGE-A3+ tumor cells was measured using a [51Cr] release assay as described previously (12, 41). In these assays, TCR-engineered PBLs were coincubated with decreasing ratios of [51Cr]-labeled target cells (E/T ratio) in AIM-V medium in 96-well U-bottom plates at 37˚C for 4 h. Lysis was measured by [51Cr] release in the medium; percent lysis = (sample release − minimum release)/(maximum release − minimum release) × 100%, average of duplicate samples.

**CD4/CD8 separation**

MAGE TCR-engineered CD4+ and CD8+ populations were separated using magnetic bead-based BD IMag human CD4 or CD8 T lymphocyte enrichment set DM kit for negative selection of those subsets (BD Biosciences).

**Lymphocyte proliferation assay**

TCR-transduced PBLs were tested for Ag-specific proliferation using the [³H]thymidine incorporation assay. Briefly, effector cells (1 × 10⁵) were cocultured with equal number of irradiated (18,000 rad, cesium source) H1299 or H1299-A2 target cells in AIM-V medium in a final volume of 0.2 ml in triplicate wells of a 96-well U-bottom microplate. The cells were cocultured for 3 d and pulsed with 1 μCi [³H]thymidine (DuPont, New England Nuclear, Shelton, CT) per well and cultured for an additional 18 h. The cells were then harvested onto a glass fiber filter (Wallac Oy, Turku, Finland), and radiomucroactivity was measured using a PerkinElmer Microbeta TriLux counter (Shelton, CT). Results expressed as cpm.

**Generation of single amino acid variants of the CDRI α-chain**

MAGE-A3: 112–120 TCR

We generated 85 single amino acid variant TCRs in four stages. 1) Site-directed mutagenesis using a QuikChange Lightning Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) was used to substitute all of the other 19 aa at position D115 introducing appropriate nucleotide changes in the PCR primer. 2) Alamine substitutions at eight of the residues F114, D115, T116, N117, Y119, K120, V121, and H122 were introduced except at position A118 that already had an alanine residue. 3) Conservative amino acid substitutions were introduced at positions N117 to Q/K/R, A118 to V/L/I, and Y119 to R/K/Q by site-directed mutagenesis. 4) Single amino acid substitutions at these three residues were synthesized (GENEART, Regensburg, Germany) to produce a 16 aa substitution library at each position. Retroviral vector supernatants expressing all of the above-mentioned single amino acid variant TCRs were generated by transient transfection into 293-GP cells; PBLs from donors were transduced and tested for tetramer binding and IFN-γ production in coculture assays with tumor cell lines.

<table>
<thead>
<tr>
<th>Table I. IFN-γ production by the TCR-transduced PBLs after coculture with tumor cell lines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cell Line</strong></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>2361</td>
</tr>
<tr>
<td>H272</td>
</tr>
<tr>
<td>1088</td>
</tr>
<tr>
<td>888</td>
</tr>
<tr>
<td>H1299</td>
</tr>
<tr>
<td>H2122</td>
</tr>
<tr>
<td>938</td>
</tr>
<tr>
<td>397-A*0201</td>
</tr>
<tr>
<td>526</td>
</tr>
<tr>
<td>1300</td>
</tr>
<tr>
<td>2984</td>
</tr>
<tr>
<td>624.38</td>
</tr>
<tr>
<td>1359-A*0201</td>
</tr>
<tr>
<td>H1299-A*0201</td>
</tr>
<tr>
<td>H1250</td>
</tr>
</tbody>
</table>

PBLs transduced with a retroviral vector expressing TCRs were cocultured with tumor cell lines. Ag-specific IFN-γ secretion was measured by ELISA. MAGE-A3/A6 and MAGE-A12 mRNA expression levels were quantitated using a quantitative real-time PCR assay. A coculture assay was done with PBLs from three donors, and the result of a representative donor is presented. Values are means of duplicate samples. Results are presented as a representative of three experiments of PBLs from separate donors.

RCC, renal cell carcinoma; SCLC, small cell lung carcinoma.
Results

Generation of MAGE-A3–reactive murine T cell clones from HLA-A*0201 transgenic mice

Transgenic mice expressing the full-length HLA-A*0201 molecule were immunized with one of the two previously identified naturally processed and presented HLA-A*0201–restricted peptides from MAGE-A3 [MAGE-A3: 112–120 (KVAELVHFL) (35) or MAGE-A3: 271–279 (FLWGPRALV) (42)] along with a helper peptide, hepatitis B virus core: 128–140. After two immunizations, murine T cells were harvested from spleen and lymph nodes and stimulated in vitro with the respective peptide and IL-2. Bulk T cell cultures from mice immunized with the MAGE-A3 peptides demonstrated specific reactivity against T2 cells pulsed with the relevant peptide and the HLA-A*0201+/MAGE-A3+ tumor cell

FIGURE 3. Specific killing of tumor cell lines by MAGE-A3 TCR-transduced PBLs. TCR-transduced human PBLs were cocultured for 4 h with the indicated 51Cr-labeled target tumor cell lines. Specific lysis of tumor cells was measured at the given E:T ratio using the formula: ([specific release − spontaneous release]/[total release − spontaneous release]). Specific lysis of untransduced, MAGE-A3: 112–120- or MAGE-A3: 271–279-specific TCR-transduced human PBLs are plotted on the graph as indicated. A, Specific lysis of melanoma tumor cell lines 1300 melanoma (HLA-A*0201+/MAGE-A3+), 526 melanoma (HLA-A*0201+/ MAGE-A3+), and 938 melanoma (HLA-A*0201+/ MAGE-A3+) by the TCR-engineered PBLs. B, Specific lysis of NSCLC cell lines H1299 (MAGE+/HLA-A2+) and H1299-A*0201 (MAGE+/HLA-A2+). C, The cytolytic activities of TCR-engineered CD8+ and CD4+ T cells were evaluated using purified lymphocytes.
lines H1299-A*0201, 1300 melanoma, and 624 melanoma after two in vitro stimulations (data not shown). Reactive T cells from positive wells were cloned by limiting dilution and tested for Ag-specific reactivity. Five clones derived from the mice immunized with the MAGE-A3: 112–120 peptide and six clones derived from the mice immunized with the MAGE-A3: 271–279 peptide that secreted high levels of IFN-γ in response to tumor cells and peptide-loaded T2 cells were expanded and further characterized.

**Cloning of MAGE-reactive TCRs**

TCR α- and β-chains from each tumor-reactive T cell clone were cloned using a SMART RACE cDNA amplification kit with gene-specific primers in the C region of mouse TCR α- and β-chains. After the identification of the variable regions of the α- and β-chains and the specific C region of the β-chain, specific primers were used to amplify the full-length TCR α- and β-chains from the cDNA. The TCR α- and β-chains were then cloned into the RNA expression vector pGEM. In vitro-transcribed RNA of TCR α- and β-chains were electroporated into human PBLs and tested for Ag-specific reactivity as described previously (39) using peptide-loaded T2 cells, H1299-A*0201, and 1300 melanoma tumor cell lines. On the basis of the specific reactivity, we selected a TCR against MAGE-A3: 112–120 peptide (TCR α-TRAVID2D-3, TCR β-TRBV29*01, and CB1) and a TCR against MAGE-A3: 271–279 peptide (TRAVID279*02, TRBV15*01, and CB2) for further evaluation.

**Construction of a MAGE-A3 TCR-expressing retroviral vector and transduction of PBLs**

Two MSGV1-based retroviral vectors with expression cassettes consisting of TCR α-TRAVID2D-3 and TCR β-TRBV29*01-CB1 and TRAV17*02 and TRBV15*01-CB2 were constructed (Fig. 1A). The TCR expression in these vectors is driven by the viral long terminal repeat, and α- and β-chains are expressed as a single open reading frame using the 2A linker peptide (13, 43). Human PBLs were stimulated for 2 d and then transduced. FACS analysis of transduced PBLs using the anti-mouse TCR β-chain revealed that both CD8+ and CD4+ cells had been transduced with these TCR vectors (Fig. 1B); however, specific tetramer binding was observed only in transduced CD8+ and not CD4+ T cells (Fig. 1C).

**Evaluation of the function of MAGE TCR-engineered PBLs**

To evaluate the recognition of the respective MAGE-A3 TCRs, transduced PBLs were subjected to coculture assay with peptide-pulsed T2 cells. TCR-transduced PBLs specifically secreted IFN-γ upon encounter with the antigenic peptide in a dose-dependent manner (Fig. 2). PBLs transduced with either MAGE-A3: 112–120 or MAGE-A3: 271–279 TCRs recognized T2 cells pulsed with as little as 0.1 ng/ml MAGE-A3 peptides, indicating that both of the TCRs were relatively high-avidity receptors. Coculture of PBLs expressing TCRs against MAGE-A3: 112–120 or MAGE-A3: 271–279 with control T2 cells that were not pulsed with any peptides produced background levels of IFN-γ. To assess the specific recognition of tumor cells, TCR-engineered PBLs were cocultured with a panel of HLA-A*0201+ and HLA-A*0201- melanoma- and lung tumor-derived cell lines. Specific release of IFN-γ was observed when the TCR-engineered PBLs were cocultured with HLA-A*0201+/MAGE-A3+ cell lines but not HLA-A*0201+/MAGE-A3- or HLA-A*0201/MAGE-A3- cell lines (Table I). A comparison of the two TCRs revealed that T cells transduced with the MAGE-A3: 112–120 TCR released ~10-fold higher levels of IFN-γ in response to HLA-A*0201+/MAGE-A3+ tumor cell targets (Table I). These responses were specific because low levels of IFN-γ were released in response to HLA-A*0201- cell lines and MAGE+/HLA-A*0201+ cell lines. Although MAGE-A3: 271–279 TCR-transduced PBLs efficiently recognized the peptide loaded on T2 cells, the recognition of MAGE-A3+/HLA-A*0201+ tumor cells as measured by the release of IFN-γ production was relatively weak (Table I).

We next measured the specific lysis of melanoma cell lines by the TCR-engineered PBLs. MAGE-A3: 112–120 TCR-transduced PBLs demonstrated superior lytic function against MAGE-A3+/HLA-A*0201+ tumor cell lines 1300 melanoma and 526 melanoma cells compared with that of MAGE-A3: 271–279 TCR-transduced PBLs (Fig. 3A). There was little or no lysis of the HLA-A*0201- cell line 938 melanoma, and the untransduced PBLs

---

**Table II. IFN-γ production by the modified MAGE-A3 A118T TCR-transduced PBLs after coculture with tumor cell lines of different histologies**

<table>
<thead>
<tr>
<th>Cell Lines</th>
<th>Histology</th>
<th>mRNA Copies/10⁶ β-Actin</th>
<th>IFN-γ (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MAGE-A3/A6</td>
<td>MAGE-A12</td>
</tr>
<tr>
<td>H1299</td>
<td>NSCLC</td>
<td>32,346</td>
<td>7,862</td>
</tr>
<tr>
<td>2361</td>
<td>RCC</td>
<td>&lt;100</td>
<td>&lt;100</td>
</tr>
<tr>
<td>888</td>
<td>Breast</td>
<td>&lt;100</td>
<td>&lt;100</td>
</tr>
<tr>
<td>MDA-4535-A*0201</td>
<td>4,437</td>
<td>629</td>
<td>325</td>
</tr>
<tr>
<td>U251</td>
<td>CNS-glione</td>
<td>3,643</td>
<td>1,087</td>
</tr>
<tr>
<td>624.38</td>
<td>Melanoma</td>
<td>41,541</td>
<td>1,040</td>
</tr>
<tr>
<td>BE-3</td>
<td>Esophageal</td>
<td>2,554</td>
<td>1,228</td>
</tr>
<tr>
<td>526</td>
<td>Melanoma</td>
<td>3,002</td>
<td>6,966</td>
</tr>
<tr>
<td>H1299-A*0201</td>
<td>NSCLC</td>
<td>57,045</td>
<td>18,875</td>
</tr>
</tbody>
</table>

Donor PBLs transduced with a retroviral vector expressing wild-type or single amino acid variants of MAGE-A3: 112–120 TCR were cocultured with tumor cell lines. Untransduced PBLs were used as controls. Ag-specific IFN-γ secretion was measured by ELISA. MAGE-A3/A6 and MAGE-A12 mRNA expression levels were estimated using a quantitative real-time PCR assays. Values are means of duplicate samples. Results are presented as a representative of two experiments using PBLs from separate donors.

RCC, renal cell carcinoma.
showed little reactivity against any of the target cells (Fig. 3A). MAGE-A3: 112–120 TCR-transduced PBLS also showed superior lytic function against NSCLC cell line H1299-A*0201+ and did not recognize the parental non-HLA-A*0201 cell line H1299 (Fig. 3B). Because tetramer binding was observed only in MAGE-A3 TCR-transduced CD8+ cells and not in CD4+ cells, we investigated IFN-γ production and cytolytic activity using purified lymphocytes. As shown in Fig. 3C, Ag-specific lysis of melanoma cell lines 1300 melanoma and 526 melanoma was evident in CD8+ cells but not seen in CD4+ cells. Similarly, IFN-γ production after coculture with tumor cells was observed only in CD8+ cells and not seen in CD4+ cells (data not shown). On the basis of these data, the MAGE-A3: 112–120 TCR was chosen for further analysis.

**Single amino acid substitution variants within CDR3 of the TCR α-chain enhance the function of TCR-engineered PBLS**

Previous studies by our group have shown that it is possible to improve the function of the TCR by engineering single or multiple amino acid changes in the CDR3 region of the TCR α-chain (14, 37, 44). We generated retroviral vectors expressing 85 single amino acid variants in the CDR3 region of the TCR α-chain and tested their function in PBLS. Preliminary screening experiments were carried out by single amino acid residue alanine substitution in the CDR3 of the α-chain. Alanine substitution at F114, D115, T116, N117, Y119, K120, and V121 completely abolished the activity of the TCR. This was seen by the complete loss of tetramer binding as well as a lack of production of IFN-γ after coculture with peptide-pulsed T2 cells or MAGE*/HLA-A*0201+ tumor cells. We next focused on position 115 and created 19 aa substitutions at this position. Complete loss of TCR activity, as seen by the complete lack of tetramer binding and loss of IFN-γ production, was observed when aspartic acid at position 115 was substituted with any of the other amino acids. Finally, we created a retroviral vector library of single amino acid variants at positions 117, 118, and 119 of the α-chain. During this screening, we found that a substitution of valine or threonine for the alanine residue present at position 118 in the wild-type α-chain retained TCR function (Fig. 4).

Table II shows the IFN-γ secretion results of a coculture assay with tumor cells of different histologies using the modified TCRs. Ag-specific HLA-A*0201–restricted recognition of tumor cells from diverse histologies were observed after coculture of TCR-engineered PBLS with breast cancer line MDA-454S-A2, glioma line U251, melanoma lines 624 and 526, esophageal line BE-3, and NSCLC line H1299-A*0201. The results demonstrated that T cells transduced with the A118V and A118T TCR variants secreted higher levels of IFN-γ than cells transduced with the wild-type TCR. T cells transduced with the A118T variant TCR secreted higher levels of IFN-γ than the A118V variant when tested against multiple MAGE*/HLA-A*0201+ cells. The HLA-A*0201+ cell lines H1299 and 888 as well as MAGE*/HLA-A*0201+ cell line 2361-RCC were not recognized by the PBLS engineered to express either the wild-type or the A118T variant, indicating that this amino acid alteration did not alter the specificity of this TCR.

To further test the function of this improved MAGE TCR, we purified the CD4+ cells and tested these cells in a coculture assay with 1300 melanoma, H1299-A*0201 NSCLC, U251 glioma, and peptide-loaded T2 cells. CD4+ cells engineered with the MAGE-A3: 112–120 TCR A118T variant specifically secreted IFN-γ in response to MAGE-A3+/HLA-A*0201+ tumor cells, whereas no response was observed in CD4+ T cells transduced with the wild-type TCR (Table III). In addition, the A118T variant led to enhanced recognition of peptide-pulsed target cells. Tetramer analysis of MAGE-A3: 112–120 A118T variant TCR-transduced PBLS showed MAGE-A3: 112–120/HLA-A*0201-specific tetramer binding in CD4+ cells, though with lesser intensity than that in CD8+ cells (Fig. 5A).

In an effort to compare the function of MAGE-A3: 112–120 wild-type and 118AT variant TCR-expressing PBLS, we performed coculture assays with MAGE-A3: 112–120 peptide-pulsed T2 cells. MAGE-A3: 112–120 A118T variant TCR-expressing PBLS produced higher levels of IFN-γ than the wild-type TCR-transduced PBLS (Fig. 5B). We also measured secretion of GM-CSF by the MAGE-A3 TCR-transduced PBLS after coculture with H1299, H1299-A2, and 624.38 cells. MAGE-A3: 112–120 118AT variant TCR-expressing PBLS produced higher levels of GM-CSF than the wild-type TCR-transduced PBLS (Fig. 5C). We then performed a cell proliferation assay to measure the Ag-specific proliferation of MAGE TCR-engineered PBLS. When cocultured with H1299-A2 tumor cell lines both MAGE-A3: 112–120 wild-type as well as 118AT variant TCR-transduced PBLS proliferated extensively as measured by the radiolabeled thymidine incorporation but not with H1299 cells (Fig. 5D). Untransduced PBLS exhibited a background level of proliferation in response to both H1299 and H1299-A2 cells.

The percentage of MAGE-A3: 112–120 wild-type or 118AT variant TCR-transduced PBLS that produced IFN-γ and IL-2 after overnight coculture with H1299-A2 cells were determined by intracellular cytokine staining. The percentage of cells that produced IFN-γ in response to Ag exposure was almost twice in number in the case of A118T variant TCR-transduced PBLS than that of wild-type TCR-expressing cells, whereas a marginal increase in the number of IL-2-producing cells was observed (Fig. 6). As a marker of degranulation, we compared the ability of MAGE-A3 wild-type and 118AT TCR-engineered PBLS to mobilize CD107a to the cell surface. MAGE TCR-transduced PBLS were cocultured with H1299 or H1299-A2 cells for 2 h and analyzed for CD107a Ag expression. A significantly higher number of MAGE-A3 A118T TCR-transduced cells stained positive for

---

**Table III. IFN-γ production by the CD4+ cells expressing wild-type or modified CDR3 amino acid variant MAGE-A3 TCRs after coculture with tumor cell lines**

<table>
<thead>
<tr>
<th>Cell Lines</th>
<th>MAGE WT</th>
<th>MAGE A118V</th>
<th>MAGE A118T</th>
</tr>
</thead>
<tbody>
<tr>
<td>1300 melanoma</td>
<td>&lt;30</td>
<td>145</td>
<td>263</td>
</tr>
<tr>
<td>H1299-A*0201 NSCLC</td>
<td>&lt;30</td>
<td>132</td>
<td>589</td>
</tr>
<tr>
<td>U251 glioma</td>
<td>&lt;30</td>
<td>110</td>
<td>666</td>
</tr>
<tr>
<td>T2 cells pulsed with MAGE peptide</td>
<td>395</td>
<td>2727</td>
<td>9710</td>
</tr>
</tbody>
</table>

CD4+ cells were purified from the donor PBLs transduced with a retroviral vector expressing wild-type or single amino acid variants of MAGE-A3: 112–120 TCR and were cocultured with tumor cell lines. Ag-specific IFN-γ secretion was measured by ELISA. Values are means of duplicate samples. Results are presented as a representative of two independent experiments using PBLS from separate donors.
Figure 5. A. Flow cytometric analysis of wild-type and modified MAGE-A3 TCR-A118T-transduced PBLs. Dot blot showing the FACS profile of PBLs stained with anti–human-CD8-FITC Ab and PE-conjugated MAGE-A3: 112–120-HLA-A*0201 tetramer. B. Recognition of MAGE-A3: 112–120 peptide-pulsed T2 cells by the MAGE-A3 TCR-transduced PBLs. Human PBLs expressing MAGE-A3: 112–120 wild-type or A118T variant TCR were cocultured for 16 h with T2 cells that were previously pulsed with different concentrations of MAGE-A3: 112–120 peptide. The concentration of IFN-γ secreted into the culture medium was measured by ELISA, and values indicate the mean of duplicate samples. C. A representative assay showing GM-CSF release data from two donors after overnight coculture with tumor cell targets. The concentration of GM-CSF secreted into the culture medium was measured by ELISA, and values indicate the mean of duplicate samples. D. Proliferation of PBLs after coculture with H1299 or H1299-A2 cells measured by [3H]thymidine incorporation after 3 d in culture. Values indicate average counts of triplicate wells.
TCRs. As seen in Table IV, superior recognition of coculture assays using PBLs transduced with the wild-type and with full-length MAGE-A3 or MAGE-A12 genes was tested in A*0201 and 293-A*0201 cells that were retrovirally transduced A3– and MAGE-A12–expressing cells. The recognition of COS7–able to recognize endogenously processed peptides from MAGE-B gnized by the TCR-engineered PBLs albeit with lower avidity tides derived from MAGE-A2 and MAGE-A6 were also reco-

Discussion
Toxicity to normal tissues is a potential negative side effect in TCR-based adoptive immunotherapy targeting shared tumor Ags that are also expressed in some normal tissue (7). Ideally, adoptive immunotherapy should strive to target T cells toward tumor-specific Ags that are not expressed in normal tissue. Toward this goal, CTAs are ideal candidates due to their overexpression in multiple tumor types and limited expression in normal tissue. MAGE-A3 is a CTA that belongs to the MAGE-A gene family and is expressed in tumors of different histologies, including melanoma, lung, ovarian, hepatocellular, head and neck, many types of sarcomas, and multiple myeloma but not found in normal tissue with the exception of testis and placenta. Because germ line cells do not present Ags due to the lack of expression of MHC molecules and can therefore not be targeted by the TCR-engineered T cells, immune responses directed against CTAs such as MAGE-A3 are not likely to lead to the recognition of these tissues.

In an attempt to derive multiple TCRs that would recognize MAGE-A3, we immunized HLA-A*0201 transgenic mice with two of the peptide epitopes that had been shown previously to be endogenously processed and presented in the context of this HLA-A2 restriction element. Expression of both TCRs in human PBLs demonstrated Ag-specific reactivity in the form of tumor cell lysis and cytokine secretion against a range of melanoma and non-melanoma tumor cell targets. Both of the TCRs equally recognized target cells pulsed with their respective MAGE-A3–derived synthetic peptides 112–120 (KVAELVHFL) and 271–279 (FLW-GPRALV); however, recognition of the tumor cells was relatively poor in the case of the TCR that recognized the 271–279 epitope. This weak recognition was evident by the relatively lower levels of IFN-γ secretion and cytolytic activity by the MAGE-A3: 271–279 TCR-engineered T cells upon coculture with MAGE-A3–positive tumor cells. However, MAGE-A3: 112–120 TCR-engineered PBLs secreted high levels of proinflammatory cytokine IFN-γ and exhibited cytolytic activity against a variety of tumor cells, including melanoma, lung, breast, esophageal, and glioma. This discrepancy could be due to the possible differences between the synthetic peptide loaded externally on T2 cells and the relatively poor efficiency in MAGE-A3 Ag processing of the 271–279 epitope observed in tumor cells (30, 45). It has been previously shown that the MAGE-A3: 271–279 epitope is not efficiently presented on the surface of tumor cell lines (46). In addition, Micconnet et al. (45) demonstrated that MAGE-A3 amino acid residues 278 and 280 are major proteasome cleavage sites but not 279. In the analysis of any TCR generated by immunization, it is critical to perform the analysis of any TCR generated by immunization, it is critical to perform
to verify the recognition of multiple tumors and not rely on a limited number of cell lines or peptide-pulsed cells because this can result in the study of pseudo-tumor Ags, which are of no clinical benefit (47).

Because the MAGE-A family of genes have 50–99% sequence homology, we made synthetic peptides of other closely related MAGE gene family peptides that differed by one or two amino acids from the MAGE-A3: 112–120 peptide. Peptides from MAGE-A3 as well as MAGE-A12 presented by the tumor cells in the context of the HLA-A*0201 allele are efficiently recognized by this TCR. The recognition of MAGE-A12 was expected based on the fact that there was a single amino acid difference between the two peptides, a conservative substitution of methionine for the valine residue present at the second position anchor residue in the MAGE-A3 peptide, both of which represent consensus amino acids (48). This might potentially broaden the number of tumors that can be targeted by this TCR. It has been reported that MAGE-A genes are coordinately expressed in tumors (49), leading to the possibility that MAGE-A3/MAGE-A12 TCR-engineered T cells may recognize peptides presented on the tumor cell surface from both the MAGE-A3 and MAGE-A12 genes, resulting in more efficient elimination of tumors with heterogeneous MAGE-A gene expression.

High-avidity recognition of tumor Ags has been shown to be important for the in vivo antitumor response (50). In an effort to enhance the function of the MAGE TCR, we introduced single amino acid substitutions in the CDR3 region of the \( \alpha \)-chain as described previously (14, 37). Modifications in the CDR3 regions can increase the Ag-specific recognition in CD4 and CD8 cells (14, 37). A TCR variant with a single amino acid substitution at position 118 from alanine to threonine of the \( \alpha \)-chain most notably enhanced CD8 T cell function and induced Ag-specific reactivity in CD4 cells that was not apparent for the wild-type TCR. Although the wild-type TCR was derived from HLA-A*0201 transgenic mice, it was not CD8-independent, a finding that we have previously reported on for an anti-CEA TCR (37). In multiple independent assays, the A118T modified TCR functionally outperformed the wild-type TCR (Figs. 5–7, Tables II–IV). Importantly, this high-avidity modified receptor retained its specificity and did not introduce any nonspecific recognition of MAGE-\( ^{\text{c}} \) or non-HLA-A*0201 cells. Preservation of TCR specificity is important to avoid potential off-target toxicity, as previously observed in some modified TCRs (14, 37, 44).

A potential advantage in targeting CTAs such as MAGE-A3 and NY ESO-1 is that the expression of these Ags can be induced selectively in tumor cells by pharmacological agents (13, 51). CTA expression on tumor cells can be induced by demethylating agents such as 5-aza-2'-deoxycytidine and histone deacetylase inhibitors such as depsipeptide. It may be an attractive clinical strategy to induce MAGE-A3 expression in the patient’s tumor before the infusion of MAGE TCR-engineered PBLs. MAGE-A3 has been the target of several clinical studies, for example, using dendritic cells loaded with MAGE-A3 peptides alone or in a pool of other melanoma Ag peptides or PBMCs pulsed with a MAGE-A3 peptide and coadministered with IL-12 (52–57). In the largest study to date, GlaxoSmithKline biologics has undertaken a MAGE-A3 protein-
based tumor vaccine multinational Phase III clinical trial to treat NSCLC patients in the adjuvant setting to prevent disease relapse (58, 59). MAGE-A3 recombinant protein vaccines have been shown to be generally well tolerated in patients, though only modest clinical responses were reported (60). Unlike peptide vaccines, recombinant protein vaccines have the potential to induce a broad array of immune responses. No significant toxicity has been reported in any of the patients treated with protein vaccines (58–61). In animal models of adoptive cell therapy, vaccination was found to be essential for effective tumor treatment (62). As we move forward with the TCR-based adoptive immunotherapy targeting MAGE-A3, combining it with a MAGE-A3 vaccine may be a useful clinical strategy to stimulate the transferred T cells in vivo after adoptive cell transfer therapy.

The MAGE-A3 TCR may be an ideal candidate for tumor immunotherapy for several reasons. First, TCR-engineered T cells can be directed against a very large variety of tumor types. Second, considering the high percentage of tumors that express MAGE genes, (for example considering the high percentage of tumors that express MAGE A3, MAGE-A12 epitopes. Finally, because MAGE is not expressed in normal tissue can be directed against a very large variety of tumor types. Second, MAGE-A3 recombinant protein vaccines have been shown of the patients treated with protein vaccines (58–61). In animal models of adoptive cell therapy, vaccination was found to be essential for effective tumor treatment (62). As we move forward with the TCR-based adoptive immunotherapy targeting MAGE-A3, combining it with a MAGE-A3 vaccine may be a useful clinical strategy to stimulate the transferred T cells in vivo after adoptive cell transfer therapy.

The MAGE-A3 TCR may be an ideal candidate for tumor immunotherapy for several reasons. First, TCR-engineered T cells can be directed against a very large variety of tumor types. Second, considering the high percentage of tumors that express MAGE genes, (for example considering the high percentage of tumors that express MAGE A3, MAGE-A12 epitopes. Finally, because MAGE is not expressed in normal tissue can be directed against a very large variety of tumor types. Second, MAGE-A3 recombinant protein vaccines have been shown of the patients treated with protein vaccines (58–61). In animal models of adoptive cell therapy, vaccination was found to be essential for effective tumor treatment (62). As we move forward with the TCR-based adoptive immunotherapy targeting MAGE-A3, combining it with a MAGE-A3 vaccine may be a useful clinical strategy to stimulate the transferred T cells in vivo after adoptive cell transfer therapy.

Acknowledgments

We thank Arnold Mixon and Shawn Farid for technical support for FACS analysis and Yong Li for technical help.

Disclosures

The authors have no financial conflicts of interest.

References

TCR RECOGNIZING MULTIPLE MAGE GENES FOR CANCER GENE THERAPY


